32-LB: Interstitial Glucose Levels during Exercise in Persons with and without Type 1 Diabetes.

Background: Using continuous glucose monitoring (CGM), we investigated potential sex-related differences in glycemia during exercise in persons living with type 1 diabetes (T1D) or without diabetes. Methods: Participants used CGM (Dexcom G6), exercise/meal diaries, or an activity monitor with a meal capture smart phone app, to help identify home based exercise and meal events over a 10 day to 4 wk period. Results: The analyses included 40 T1D (age: 36±15 yrs; BMI: 26.3±3.1 kg/m2; HbA1c: 7.5±1.5%; 35% female; mean±SD) and 120 persons without diabetes (age: 30±20 years; BMI: 24.4±3.2 kg/m2; HbA1c: 5.1±0.3; 64% female) and 283 and 619 exercise events, respectively. The frequency distribution of all CGM values were comparable between males and females overall, but values had a wider distribution among T1D as compared to non-T1D (Fig). Hyperglycemia (> 180 mg/dL) represented ~0.1% of the exercise time in participants without T1D vs. 31% and 24% of the time in the female and male participants without diabetes, respectively. Hypoglycemic values (<70 mg/dL) represented 7.1% and 3.0% of the time in the non-T1D females and males, respectively (P<0.001), vs. 4.4% and 5.0% in the T1D females and males (P=0.67), respectively. Conclusions: Based on CGM, mild hypoglycemic exposure during exercise is surprisingly common in individuals with and without diabetes and may be particularly prevalent in females without diabetes. Disclosure: M. Riddell: Advisory Panel; Self; Zealand Pharma A/S. Consultant; Self; Lilly Diabetes. Research Support; Self; Dexcom, Inc., Insulet Corporation. Speaker's Bureau; Self; Novo Nordisk Inc., Sanofi. Stock/Shareholder; Self; Zucara Therapeutics Inc. Z. Li: None. N. DSouza: None. C. Yeung: None. D. Kesibi: None. S. R. Patton: None. R. Beck: Consultant; Self; Bigfoot Biomedical, Inc., Diasome Pharmaceuticals, Inc., Insulet Corporation, Lilly Diabetes, vTv Therapeutics. Research Support; Self; Beta Bionics, Inc., Dexcom, Inc., Medtronic, Novo Nordisk, Tandem Diabetes Care. P. G. Jacobs: Board Member; Self; Pacific Diabetes Technologies. Research Support; Self; Dexcom, Inc. M. A. Clements: Consultant; Self; Eli Lilly and Company. Employee; Self; Glooko, Inc. Research Support; Self; Abbott Diabetes, Dexcom, Inc. R. L. Gal: None. F. J. Doyle: Advisory Panel; Self; Mode AGC. Other Relationship; Self; Dexcom, Inc., Insulet Corporation, Roche Diabetes Care. C. K. Martin: Advisory Panel; Self; EHE Health. Board Member; Self; NaturallySlim. Research Support; Self; American Society for Nutrition, Leona M. and Harry B. Helmsley Charitable Trust, Lilly, National Institutes of Health, Patient-Centered Outcomes Research Institute, U. S. Department of Agriculture, WW. Other Relationship; Self; ABGIL, Academy of Nutrition and Dietetics. P. Calhoun: None. J. Sherr: Advisory Panel; Self; Cecelia Health, Insulet Corporation, Medtronic. Consultant; Self; Insulet Corporation, Lexicon Pharmaceuticals, Inc., Lilly Diabetes, Medtronic. Research Support; Self; Dexcom, Inc., Insulet Corporation, Medtronic. Speaker's Bureau; Self; Lilly Diabetes. J. R. Castle: Advisory Panel; Self; Novo Nordisk, Zealand Pharma A/S. Consultant; Self; ADOCIA. Research Support; Self; Dexcom, Inc. Stock/Shareholder; Spouse/Partner; Insulet Corporation. Stock/Shareholder; Self; Pacific Diabetes Technologies. M. R. Rickels: Advisory Panel; Self; Semma Therapeutics, Sernova, Corp. Research Support; Self; Xeris Pharmaceuticals, Inc. [ABSTRACT FROM AUTHOR]